Bernadette de Rauglaudre

Years Active: 2022-2022
Publications (10 Years): 3

This page only lists publications with an associated author ORCID identifier.

Publications

Bernadette de Rauglaudre, Camille Sibertin-Blanc, Aurélie Fabre, Karine Le Malicot, Jaafar Bennouna, François Ghiringhelli, Julien Taïeb, Valérie Boige, Olivier Bouché, Thierry Chatellier, Roger Faroux, Eric François, Stéphane Jacquot, Dominique Genet, Claire Mulot, Sylviane Olschwang, Jean-François Seitz, Thomas Aparicio, Laetitia Dahan
Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial. Therapeutic advances in medical oncology 14 (2022)
Bernadette de Rauglaudre, Pascal Finetti, David Jérémie Birnbaum, Marc Lopez, François Bertucci, Emilie Mamessier
First-in-Human, Phase I Study of PCA062 in Solid Tumors-Letter. Molecular cancer therapeutics 21 (11) (2022)
Bernadette de Rauglaudre, Camille Sibertin-Blanc, Aurélie Fabre, Karine Le Malicot, Jaafar Bennouna, François Ghiringhelli, Julien Taïeb, Valérie Boige, Olivier Bouché, Thierry Chatellier, Roger Faroux, Eric François, Stéphane Jacquot, Dominique Genet, Claire Mulot, Sylviane Olschwang, Jean-François Seitz, Thomas Aparicio, Laetitia Dahan
Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial. Therapeutic advances in medical oncology 14 (2022)

Bernadette de Rauglaudre.css-eqlu8i{font-size:small;padding-left:4px;}